Literature DB >> 29276872

Successful treatment of a childhood synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome with subcutaneous methotrexate: A case report.

Meltem Akçaboy1, Sevcan Azime Bakkaloğlu-Ezgü1, Bahar Büyükkaragöz1, Emel Isıyel1, Yasar Kandur1, Enver Hasanoğlu1, Necla Buyan1.   

Abstract

Akçaboy M, Bakkaloğlu-Ezgü SA, Büyükkaragöz B, Isıyel E, Kandur Y, Hasanoğlu E, Buyan N. Successful treatment of a childhood synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome with subcutaneous methotrexate: A case report. Turk J Pediatr 2017; 59: 184-188. SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis and osteitis) is defined as a syndrome that is related to various osteoarticular manifestations and chronic dermatological conditions especially severe acne. SAPHO syndrome is a rare and unusual clinical entity in childhood and treatment choices are variable. We report an 11-year-old girl who suffered from SAPHO syndrome and successfully treated with subcutaneous methotrexate. We report our case in order to take attention to this rare clinical condition in evaluating patients and also to point out that treatment options beyond biologic agents should be the first line treatment in childhood.

Entities:  

Keywords:  SAPHO syndrome; children; methotrexate; treatment

Mesh:

Substances:

Year:  2017        PMID: 29276872     DOI: 10.24953/turkjped.2017.02.011

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  2 in total

1.  Pediatric Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO) Syndrome: Diagnostic Challenges and Treatment Approach.

Authors:  Niki Kyriazi; Yvonne-Mary Papamerkouriou; Despoina Maritsi; Maria Angela Dargara; John Michelarakis
Journal:  Cureus       Date:  2020-04-09

2.  Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.

Authors:  Ben Li; Guan-Wu Li; Luan Xue; Yue-Ying Chen
Journal:  World J Clin Cases       Date:  2020-10-06       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.